Equity Profile

RDY

Dr. Reddy's Laboratories Limited

Health CarePharmaceuticals$10.8B

May12Tue

Pre-Earnings Brief

UpcomingQ4-2026Pre-Market9:00 AM EDT

Company Snapshot

Dr. Reddy's Laboratories Limited is a major player in the pharmaceuticals sector, focusing on producing a wide range of medications, including generic and branded drugs....

Key Metrics to Watch

Revenue Growth

Investors will be looking for signs of growth in sales, especially in key markets.

N/A

Earnings Per Share (EPS)

EPS is a critical measure of profitability, and any significant change can impact investor sentiment.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RDY Q4-2026 Earnings Preview

Context

Company Snapshot

Dr. Reddy's Laboratories Limited is a major player in the pharmaceuticals sector, focusing on producing a wide range of medications, including generic and branded drugs. With a market cap of $11 billion, the company plays a crucial role in healthcare, especially in emerging markets, where access to affordable medications is vital.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

+0.00%

Avg Stock Reaction

-2.67%

Last Quarter Recap

In the last quarter, Dr. Reddy's continued to navigate challenges in the pharmaceutical landscape, focusing on expanding its product portfolio and market presence. The company has been working on enhancing its operational efficiencies.

Management Promises & Guidance

Commitment to increasing R&D investments to drive innovation.
Focus on expanding into new markets, particularly in Asia.
Plans to streamline operations to reduce costs.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the market awaits clarity on revenue growth and profitability. Investors are keen to see how the company is managing competition and regulatory challenges.

Bull Case

If Dr. Reddy's shows strong revenue growth and effective cost management, it could signal a robust recovery and attract more investors.

Bear Case

Conversely, if the earnings report reveals declining sales or increased costs, it could lead to negative sentiment and a drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate in key markets?

This metric will indicate how well Dr. Reddy's is performing against competitors and whether it is gaining or losing market share.

How is the company managing its cost structure?

Cost management is crucial for maintaining profitability, especially in a competitive pharmaceutical landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Dr. Reddy's to capture market share in emerging markets, which could drive unexpected revenue growth.

Supporting Evidence

Options pricing suggests a larger move than historical averages, indicating potential surprises.

Past performance shows that the company has rebounded strongly after previous earnings misses.

Key Risk

If revenue growth exceeds expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Dr. Reddy's can sustain growth amidst increasing competition and regulatory pressures.

Bull Confirmed If

Revenue growth of at least 10% year-over-year would confirm the bull case.

Bear Confirmed If

A revenue decline of more than 5% would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±8.11%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±8.1% while RDY has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

30d HV

31.2%

Calls (33K)P/C Ratio: 0.00Puts (100)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

13.94%

of float

Insider

0.00%

of float

Holders

323

institutions

Top Holders· as of Mar 2026

Robeco Institutional Asset Management B.V.
17,177,882 sh · $234.8M
2.06%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dr. Reddy's beats expectations, history suggests a potential stock increase of around 5.5%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may experience muted movement as investors reassess future growth.

Miss

A miss could lead to a decline in stock price, with historical patterns suggesting a drop of around 8%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth in emerging markets.
2Updates on cost management strategies.
3Any new product launches or pipeline developments.
4Insights into competitive positioning in key therapeutic areas.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

RadNet, Inc.

Company Snapshot

Dr. Reddy's Laboratories Limited is a major player in the pharmaceuticals sector, focusing on producing a wide range of medications, including generic and branded drugs....

Key Metrics to Watch

Revenue Growth

Investors will be looking for signs of growth in sales, especially in key markets.

N/A

Earnings Per Share (EPS)

EPS is a critical measure of profitability, and any significant change can impact investor sentiment.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RDY Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

+0.00%

Avg Stock Reaction

-2.67%

Last Quarter Recap

Management Promises & Guidance

Commitment to increasing R&D investments to drive innovation.
Focus on expanding into new markets, particularly in Asia.
Plans to streamline operations to reduce costs.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the market awaits clarity on revenue growth and profitability. Investors are keen to see how the company is managing competition and regulatory challenges.

Bull Case

If Dr. Reddy's shows strong revenue growth and effective cost management, it could signal a robust recovery and attract more investors.

Bear Case

Conversely, if the earnings report reveals declining sales or increased costs, it could lead to negative sentiment and a drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate in key markets?

This metric will indicate how well Dr. Reddy's is performing against competitors and whether it is gaining or losing market share.

How is the company managing its cost structure?

Cost management is crucial for maintaining profitability, especially in a competitive pharmaceutical landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Dr. Reddy's to capture market share in emerging markets, which could drive unexpected revenue growth.

Supporting Evidence

Options pricing suggests a larger move than historical averages, indicating potential surprises.

Past performance shows that the company has rebounded strongly after previous earnings misses.

Key Risk

If revenue growth exceeds expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Dr. Reddy's can sustain growth amidst increasing competition and regulatory pressures.

Bull Confirmed If

Revenue growth of at least 10% year-over-year would confirm the bull case.

Bear Confirmed If

A revenue decline of more than 5% would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±8.11%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±8.1% while RDY has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

30d HV

31.2%

Calls (33K)P/C Ratio: 0.00Puts (100)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

13.94%

of float

Insider

0.00%

of float

Holders

323

institutions

Top Holders· as of Mar 2026

Robeco Institutional Asset Management B.V.
17,177,882 sh · $234.8M
2.06%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dr. Reddy's beats expectations, history suggests a potential stock increase of around 5.5%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may experience muted movement as investors reassess future growth.

Miss

A miss could lead to a decline in stock price, with historical patterns suggesting a drop of around 8%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth in emerging markets.
2Updates on cost management strategies.
3Any new product launches or pipeline developments.
4Insights into competitive positioning in key therapeutic areas.